External validation of the PROGRESS-CTO complication risk scores: Individual patient data pooled analysis of 3 registries.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 03 2023
Historique:
received: 21 10 2022
revised: 12 12 2022
accepted: 19 12 2022
pubmed: 25 12 2022
medline: 15 2 2023
entrez: 24 12 2022
Statut: ppublish

Résumé

Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with a considerable risk of complications, and risk stratification is of utmost importance. To assess the clinical usefulness of the recently developed PROGRESS-CTO (NCT02061436) complication risk scores in an independent cohort. Individual patient data pooled analysis of 3 registries was performed. Of the 4569 patients who underwent CTO PCI, 102 (2.2%) had major adverse cardiovascular events (MACE). Patients with MACE were older (69 ± 11 vs. 65 ± 10, p < 0.001), more likely to have a history of prior coronary artery bypass graft surgery, and unfavorable angiographic characteristics J-CTO score (2.4 ± 1.2 vs. 2.1 ± 1.3, p = 0.007), including blunt stump (59% vs. 49%, p = 0.047). Technical success was lower in patients with MACE (59% vs. 86%, p < 0.001). The area under the receiver operating characteristic curve of the PROGRESS-CTO complication risk models were as follows: MACE 0.72 (95% confidence interval [CI], 0.67-0.76), mortality 0.73 (95% CI, 0.61-0.85), and pericardiocentesis 0.69 (95% CI, 0.62-0.77) in the validation dataset. The observed complication rates increased with higher PROGRESS-CTO complication scores. The PROGRESS-CTO MACE score showed good calibration in this external cohort, with MACE rates similar to the original study: 0.7% (score 0-1), 1.5% (score 2), 2.2% (score 3), 3.8% (score 4), 4.9% (score 5), 5.8% (score 6-7). Given the good discriminative performance, calibration, and ease of calculation, the PROGRESS-CTO complication scores could help assess the risk of complications in patients undergoing CTO PCI.

Sections du résumé

BACKGROUND
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with a considerable risk of complications, and risk stratification is of utmost importance.
AIMS
To assess the clinical usefulness of the recently developed PROGRESS-CTO (NCT02061436) complication risk scores in an independent cohort.
METHODS
Individual patient data pooled analysis of 3 registries was performed.
RESULTS
Of the 4569 patients who underwent CTO PCI, 102 (2.2%) had major adverse cardiovascular events (MACE). Patients with MACE were older (69 ± 11 vs. 65 ± 10, p < 0.001), more likely to have a history of prior coronary artery bypass graft surgery, and unfavorable angiographic characteristics J-CTO score (2.4 ± 1.2 vs. 2.1 ± 1.3, p = 0.007), including blunt stump (59% vs. 49%, p = 0.047). Technical success was lower in patients with MACE (59% vs. 86%, p < 0.001). The area under the receiver operating characteristic curve of the PROGRESS-CTO complication risk models were as follows: MACE 0.72 (95% confidence interval [CI], 0.67-0.76), mortality 0.73 (95% CI, 0.61-0.85), and pericardiocentesis 0.69 (95% CI, 0.62-0.77) in the validation dataset. The observed complication rates increased with higher PROGRESS-CTO complication scores. The PROGRESS-CTO MACE score showed good calibration in this external cohort, with MACE rates similar to the original study: 0.7% (score 0-1), 1.5% (score 2), 2.2% (score 3), 3.8% (score 4), 4.9% (score 5), 5.8% (score 6-7).
CONCLUSION
Given the good discriminative performance, calibration, and ease of calculation, the PROGRESS-CTO complication scores could help assess the risk of complications in patients undergoing CTO PCI.

Identifiants

pubmed: 36565956
pii: S0167-5273(22)01921-0
doi: 10.1016/j.ijcard.2022.12.036
pii:
doi:

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-20

Commentaires et corrections

Type : CommentOn

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Bahadir Simsek (B)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Peter Tajti (P)

The Gottsegen National Cardiovascular Center, Budapest, Hungary.

Mauro Carlino (M)

Interventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.

Soledad Ojeda (S)

Division of Interventional Cardiology, Reina Sofia Hospital, University of Cordoba, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Cordoba, Spain.

Manuel Pan (M)

Division of Interventional Cardiology, Reina Sofia Hospital, University of Cordoba, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Cordoba, Spain.

Stephane Rinfret (S)

Emory Heart and Vascular Center, Emory University School of Medicine, Atlanta, GA, USA.

Evangelia Vemmou (E)

Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

Spyridon Kostantinis (S)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Ilias Nikolakopoulos (I)

Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

Judit Karacsonyi (J)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Joseph A Dens (JA)

Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.

Pierfrancesco Agostoni (P)

Hartcentrum, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium.

Khaldoon Alaswad (K)

Henry Ford Health System, Detroit, MI, USA.

Michael Megaly (M)

Division of Cardiology, Willis Knighton Heart Institute, Shreveport, LA, United States of America.

Alexandre Avran (A)

Department of Interventional Cardiology, Clinique Pasteur, Essey-lès-Nancy, France.

James W Choi (JW)

Presbyterian Hospital, Dallas, TX, USA.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Darshan Doshi (D)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Dimitri Karmpaliotis (D)

Morristown Medical Center, Morristown, NJ, USA.

Jaikirshan J Khatri (JJ)

Cleveland Clinic Foundation, Cleveland, OH, USA.

Paul Knaapen (P)

Department of Cardiology, VU University Medical Center, Amsterdam, the Netherlands.

Alessio La Manna (A)

University of Catania, Catania, Italy.

James C Spratt (JC)

St. George's University Healthcare NHS Trust, London, United Kingdom.

Masaki Tanabe (M)

Department of Cardiology, Nozaki Tokushukai Hospital, Osaka, Japan.

Simon Walsh (S)

Belfast Health, Belfast, United Kingdom.

Olga C Mastrodemos (OC)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Salman Allana (S)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Athanasios Rempakos (A)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Bavana V Rangan (BV)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Omer Goktekin (O)

Division of Cardiology, Memorial Bahcelievler Hospital, Istanbul, Turkey.

Sevket Gorgulu (S)

Division of Cardiology, Biruni University School of Medicine, Istanbul, Turkey.

Paul Poommipanit (P)

University Hospitals, Cleveland, OH, USA.

Kathleen E Kearney (KE)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

William L Lombardi (WL)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

J Aaron Grantham (JA)

Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.

Kambis Mashayekhi (K)

Heart Center Lahr, Department for Internal Medicine and Cardiology, Germany.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Lorenzo Azzalini (L)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: azzalini@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH